|
Market Closed -
Hong Kong S.E.
04:08:16 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 3.095 HKD | +3.17% |
|
-7.89% | +4.92% |
| 08-31 | HighTide Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 07-02 | HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns | MT |
Company Valuation: HighTide Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Market Cap 1 | 6,056 | 614.3 | 1,515 |
| Change | - | -89.86% | 146.54% |
| Enterprise Value (EV) 1 | 5,336 | 201.5 | 1,139 |
| Change | - | -96.22% | 464.94% |
| P/E | -3.25x | -1.41x | -5.19x |
| PBR | 8.62x | 1.45x | 4.93x |
| PEG | 0.2x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -11.9x | -0.45x | -5.13x |
| EV / EBIT | -11.9x | -0.45x | -5.09x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -3.617 | -0.8445 | -0.5106 |
| Distribution rate | - | - | - |
| Net sales | - | - | - |
| EBITDA 1 | -447.7 | -443.7 | -222.2 |
| EBIT 1 | -448.2 | -444.8 | -223.6 |
| Net income 1 | -939.3 | -381.8 | -245 |
| Net Debt 1 | -719.9 | -412.8 | -376 |
| Reference price 2 | 11.764 | 1.193 | 2.651 |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | 571,326 |
| Announcement Date | 4/26/24 | 4/23/25 | 4/29/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 218M | |
| 20.07x | 7.14x | 14.31x | 1.48% | 68.98B | |
| 28.61x | 7.85x | 24.63x | 0.05% | 53.15B | |
| 35.29x | 6.26x | 18.73x | 0.92% | 50.83B | |
| 34.21x | 3.36x | 14.49x | -.--% | 44.61B | |
| -19.62x | 197.94x | -20.83x | -.--% | 40.57B | |
| 49.56x | 5.68x | 31.19x | -.--% | 42.53B | |
| 27.19x | 7.72x | 19.99x | 0.39% | 30.95B | |
| 29.37x | 6.23x | 16.17x | -.--% | 25.44B | |
| -13.66x | 5.14x | -6.23x | -.--% | 22.66B | |
| Average | 21.22x | 27.48x | 12.49x | 0.32% | 37.99B | |
| Weighted average by Cap. | 23.22x | 26.76x | 13.87x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2511 Stock
- Valuation HighTide Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
